BioNTech Announces Third Quarter 2021 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
BioNTech (BNTX) PT Lowered to $289 at Goldman Sachs
November 11, 2021 7:19 AM ESTGoldman Sachs analyst Chris Shibutani lowered the price target on BioNTech (NASDAQ: BNTX) to $289.00 (from $433.00) while maintaining a Neutral rating.
The analyst commented, "While vaccine marketplace trends continue to provide tailwinds for mRNA-vaccine manufacturers, more hesitant management commentary around the endemic phase... More
BioNTech SE (BNTX) Reports Q3 EPS of EUR12.35
November 9, 2021 6:47 AM ESTBioNTech SE (NASDAQ: BNTX) reported Q3 EPS of EUR12.35, versus (EUR0.88) reported last year. Revenue for the quarter came in at EUR6.09 billion, versus EUR67.5 million reported last year.
Guidance:
Estimated BioNTech COMIRNATY/COVID-19 vaccine revenues for the full 2021... More
